Malignant neoplasm of liver
|
0.400 |
Biomarker
|
disease |
BEFREE |
These findings indicate that BCA exerts its cytotoxic effects by promoting phosphorylation/ubiquitin-dependent degradation of β-catenin and may potentially serve as a chemopreventive agent for colonrectal and liver cancers.
|
31163223 |
2019 |
Malignant neoplasm of liver
|
0.400 |
Biomarker
|
disease |
BEFREE |
Tcf7l1 Acts as a Suppressor for the Self-Renewal of Liver Cancer Stem Cells and Is Regulated by IGF/MEK/ERK Signaling Independent of β-Catenin.
|
31322782 |
2019 |
Malignant neoplasm of liver
|
0.400 |
Biomarker
|
disease |
BEFREE |
Long non-coding RNA THOR promotes liver cancer stem cells expansion via β-catenin pathway.
|
30359743 |
2019 |
Malignant neoplasm of liver
|
0.400 |
Biomarker
|
disease |
BEFREE |
Anti-tumor effect of LATS2 on liver cancer death: Role of DRP1-mediated mitochondrial division and the Wnt/β-catenin pathway.
|
30981110 |
2019 |
Malignant neoplasm of liver
|
0.400 |
Biomarker
|
disease |
BEFREE |
In conclusion, this study revealed that the reciprocal regulation between O-GlcNAcylation and β-catenin facilitated the proliferation of liver cancer.
|
30762425 |
2019 |
Malignant neoplasm of liver
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Ribose-5-phosphate isomerase A overexpression promotes liver cancer development in transgenic zebrafish via activation of ERK and β-catenin pathways.
|
30418535 |
2019 |
Malignant neoplasm of liver
|
0.400 |
Biomarker
|
disease |
BEFREE |
Using data from The Cancer Genome Atlas, from the LIRI-JP (Liver Cancer - RIKEN, JP project), and from our transcriptomic, transfection and mouse transgenic experiments, we identify a GRN which functionally links LIN28B-dependent dedifferentiation with dysfunction of β-catenin (CTNNB1).
|
30953666 |
2019 |
Malignant neoplasm of liver
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Mutations in <i>CTNNB1</i>, the gene encoding β-catenin, are common in colon and liver cancers, the most frequent mutation affecting Ser-45 in β-catenin.
|
31690625 |
2019 |
Malignant neoplasm of liver
|
0.400 |
Biomarker
|
disease |
BEFREE |
β2 spectrin-mediated differentiation repressed the properties of liver cancer stem cells through β-catenin.
|
29555987 |
2018 |
Malignant neoplasm of liver
|
0.400 |
Biomarker
|
disease |
BEFREE |
Significantly, we also found that excessive β-catenin abrogated the effect of MEG3 in liver cancer.
|
29449541 |
2018 |
Malignant neoplasm of liver
|
0.400 |
Biomarker
|
disease |
BEFREE |
Mefloquine targets β-catenin pathway and thus can play a role in the treatment of liver cancer.
|
29578061 |
2018 |
Malignant neoplasm of liver
|
0.400 |
Biomarker
|
disease |
BEFREE |
Thyroid Hormone Receptor-β Agonist GC-1 Inhibits Met-β-Catenin-Driven Hepatocellular Cancer.
|
28807594 |
2017 |
Malignant neoplasm of liver
|
0.400 |
Biomarker
|
disease |
BEFREE |
Let7b modulates the Wnt/β-catenin pathway in liver cancer cells via downregulated Frizzled4.
|
28671046 |
2017 |
Malignant neoplasm of liver
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The liver cancer-specific signature 16, associated with alcohol, displays a unique feature of transcription-coupled damage and is the main source of CTNNB1 mutations.
|
29101368 |
2017 |
Malignant neoplasm of liver
|
0.400 |
Biomarker
|
disease |
BEFREE |
Collectively, we conclude that suppression of both Sirt1 and Wnt/βCatenin might be effective in treating liver cancer.
|
28583374 |
2017 |
Malignant neoplasm of liver
|
0.400 |
Biomarker
|
disease |
BEFREE |
Knockout of ASIC1a by CRISPR/CAS9 inhibited liver cancer cell proliferation and tumorigenicity in vitro and in vivo through β-catenin degradation and LEF-TCF inactivation.
|
27462920 |
2017 |
Malignant neoplasm of liver
|
0.400 |
Biomarker
|
disease |
BEFREE |
Oncogenic dependency on β-catenin in liver cancer cell lines correlates with pathway activation.
|
29383099 |
2017 |
Malignant neoplasm of liver
|
0.400 |
Biomarker
|
disease |
BEFREE |
Wnt/β-catenin activation and macrophage induction during liver cancer development following steatosis.
|
28671671 |
2017 |
Malignant neoplasm of liver
|
0.400 |
Biomarker
|
disease |
BEFREE |
Targeting β-catenin in hepatocellular cancers induced by coexpression of mutant β-catenin and K-Ras in mice.
|
27981621 |
2017 |
Malignant neoplasm of liver
|
0.400 |
Biomarker
|
disease |
BEFREE |
We studied T-UCRs downstream of the Wnt/β-catenin pathway in liver cancer.
|
27618837 |
2017 |
Malignant neoplasm of liver
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Antitumour activity of an inhibitor of miR-34a in liver cancer with β-catenin-mutations.
|
25792709 |
2016 |
Malignant neoplasm of liver
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Hepatic cancer stem cell marker granulin-epithelin precursor and β-catenin expression associate with recurrence in hepatocellular carcinoma.
|
26942873 |
2016 |
Malignant neoplasm of liver
|
0.400 |
Biomarker
|
disease |
BEFREE |
We aim to review the role of β-catenin pathway on hepatocarcinogenesis and liver cancer stem cell maintenance.
|
26811628 |
2016 |
Malignant neoplasm of liver
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
These results suggest that most colorectal and liver cancers with mutations in components of the β-catenin degradation complex do not strongly rely on extracellular Wnt ligand exposure to support optimal growth.
|
27851986 |
2016 |
Malignant neoplasm of liver
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, using TOPflash and reverse transcription‑quantitative polymerase chain reaction analysis, Wnt/β‑catenin signaling and the transcriptional regulation of Wnt/β‑catenin target genes including dickkopf Wnt signaling pathway inhibitor 1, axis inhibition protein 2 and cyclin D1 were observed to be markedly upregulated in liver cancer SP cells.
|
26956539 |
2016 |